CRO Stocks Lead Gains as Biopharma Investment and Cross-Border Deals Rebound

Stock News10:58

CRO concept stocks are leading the gains in Hong Kong trading. By the time of writing, VIVA BIOTECH (01873) rose 6.14% to HK$2.42, WUXI BIO (02269) increased 6.01% to HK$40.54, TIGERMED (03347) climbed 4.65% to HK$56.3, and WUXI APPTEC (02359) advanced 4.31% to HK$121.

Positive news includes projected net profit growth for WUXI APPTEC by 103% year-on-year in 2025, while TIGERMED is expected to see an increase of 105–204%. Global biopharmaceutical investment and financing began to recover in 2025, with year-on-year growth rates of 2.7% globally and 6.4% in China. Innovation drug development remains robust, with business development (BD) transaction value reaching US$135.7 billion in 2025, up 143% year-on-year.

According to a research report, as financing and BD-related payments improve, pharmaceutical companies are increasing their investments in clinical trials again. Demand for outsourced clinical CRO, SMO, and regulatory services has also rebounded, providing direct funding and project pipelines for the sector's recovery. Another securities firm noted that CXO and upstream research sectors primarily serve the R&D and late-stage production of innovative drugs. With the strong momentum in drug development, both segments are expected to maintain favorable performance trends.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176500753?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 10:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176500753","market":"sh","top_or_hot":-1,"title":"CRO Stocks Lead Gains as Biopharma Investment and Cross-Border Deals Rebound","media":"Stock News","content":"<p>CRO concept stocks are leading the gains in Hong Kong trading. By the time of writing, VIVA BIOTECH (01873) rose 6.14% to HK$2.42, WUXI BIO (02269) increased 6.01% to HK$40.54, TIGERMED (03347) climbed 4.65% to HK$56.3, and WUXI APPTEC (02359) advanced 4.31% to HK$121.</p>\n<p>Positive news includes projected net profit growth for WUXI APPTEC by 103% year-on-year in 2025, while TIGERMED is expected to see an increase of 105–204%. Global biopharmaceutical investment and financing began to recover in 2025, with year-on-year growth rates of 2.7% globally and 6.4% in China. Innovation drug development remains robust, with business development (BD) transaction value reaching US$135.7 billion in 2025, up 143% year-on-year.</p>\n<p>According to a research report, as financing and BD-related payments improve, pharmaceutical companies are increasing their investments in clinical trials again. Demand for outsourced clinical CRO, SMO, and regulatory services has also rebounded, providing direct funding and project pipelines for the sector's recovery. Another securities firm noted that CXO and upstream research sectors primarily serve the R&D and late-stage production of innovative drugs. With the strong momentum in drug development, both segments are expected to maintain favorable performance trends.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CRO Stocks Lead Gains as Biopharma Investment and Cross-Border Deals Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCRO Stocks Lead Gains as Biopharma Investment and Cross-Border Deals Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-10 10:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CRO concept stocks are leading the gains in Hong Kong trading. By the time of writing, VIVA BIOTECH (01873) rose 6.14% to HK$2.42, WUXI BIO (02269) increased 6.01% to HK$40.54, TIGERMED (03347) climbed 4.65% to HK$56.3, and WUXI APPTEC (02359) advanced 4.31% to HK$121.</p>\n<p>Positive news includes projected net profit growth for WUXI APPTEC by 103% year-on-year in 2025, while TIGERMED is expected to see an increase of 105–204%. Global biopharmaceutical investment and financing began to recover in 2025, with year-on-year growth rates of 2.7% globally and 6.4% in China. Innovation drug development remains robust, with business development (BD) transaction value reaching US$135.7 billion in 2025, up 143% year-on-year.</p>\n<p>According to a research report, as financing and BD-related payments improve, pharmaceutical companies are increasing their investments in clinical trials again. Demand for outsourced clinical CRO, SMO, and regulatory services has also rebounded, providing direct funding and project pipelines for the sector's recovery. Another securities firm noted that CXO and upstream research sectors primarily serve the R&D and late-stage production of innovative drugs. With the strong momentum in drug development, both segments are expected to maintain favorable performance trends.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VT","symbol_name":"世界全股市ETF-Vanguard","start_time":0,"source_url":"","article_id":"1176500753","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176500753","pubTimestamp":1770692300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CRO concept stocks are leading the gains in Hong Kong trading. By the time of writing, VIVA BIOTECH (01873) rose 6.14% to HK$2.42, WUXI BIO (02269) increased 6.01% to HK$40.54, TIGERMED (03347)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","VT":"世界全股市ETF-Vanguard","LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0823426308.USD":"法巴中国股票基金","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","BK1589":"北水核心资产","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","02359":"药明康德","BK4588":"碎股","02269":"药明生物","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","03347":"泰格医药","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0051755006.USD":"摩根大通中国A (dist)","LU1720050803.USD":"安联全方位中国股票基金","BK1576":"医药外包概念","LU0140636845.USD":"施罗德大中华区股票A Acc","BK1141":"生命科学工具和服务","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","01873":"维亚生物","BK1610":"ETF&股票定投概念","BK1161":"生物科技","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0052750758.USD":"富兰克林中国基金A Acc","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","06978":"永泰生物-B","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","BK1574":"生物医药B类股","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","BK1583":"高瓴概念","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","VXUS":"国际股票ETF-Vanguard","BK1521":"挪威政府全球养老基金持仓","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC"},"translate_title":"随着生物制药投资和跨境交易反弹，CRO股票领涨","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"02269":1,"06978":1,"03347":1,"VXUS":1,"VT":1,"01873":1,"02359":1},"content_text":"CRO concept stocks are leading the gains in Hong Kong trading. By the time of writing, VIVA BIOTECH (01873) rose 6.14% to HK$2.42, WUXI BIO (02269) increased 6.01% to HK$40.54, TIGERMED (03347) climbed 4.65% to HK$56.3, and WUXI APPTEC (02359) advanced 4.31% to HK$121.\nPositive news includes projected net profit growth for WUXI APPTEC by 103% year-on-year in 2025, while TIGERMED is expected to see an increase of 105–204%. Global biopharmaceutical investment and financing began to recover in 2025, with year-on-year growth rates of 2.7% globally and 6.4% in China. Innovation drug development remains robust, with business development (BD) transaction value reaching US$135.7 billion in 2025, up 143% year-on-year.\nAccording to a research report, as financing and BD-related payments improve, pharmaceutical companies are increasing their investments in clinical trials again. Demand for outsourced clinical CRO, SMO, and regulatory services has also rebounded, providing direct funding and project pipelines for the sector's recovery. Another securities firm noted that CXO and upstream research sectors primarily serve the R&D and late-stage production of innovative drugs. With the strong momentum in drug development, both segments are expected to maintain favorable performance trends.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176500753","isCrawlerRequest":true}